Eisai Co., Ltd. announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical (Hangzhou) Co., Ltd., for BB-1701, an...
Eisai Co., Ltd. today announced the completion of a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan), which is a part of strategic...
Eisai Co., Ltd. today announced an article about long-term health outcomes of anti-amyloid-beta (Aβ) protofibril* antibody lecanemab in people living with mild cognitive...
Eisai Co., Ltd. announced today that it has entered into an agreement with the National Cancer Center to collaborate on investigator-initiated clinical research...
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201),...
Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg),...